| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms, Castration-Resistant | 15 | 2023 | 475 | 1.720 |
Why?
|
| src-Family Kinases | 6 | 2014 | 487 | 1.060 |
Why?
|
| Thiazoles | 7 | 2013 | 729 | 1.020 |
Why?
|
| Prostatic Neoplasms | 16 | 2024 | 5990 | 0.870 |
Why?
|
| Bone Neoplasms | 11 | 2019 | 2668 | 0.780 |
Why?
|
| Pyrimidines | 7 | 2013 | 3666 | 0.570 |
Why?
|
| Taxoids | 4 | 2017 | 1008 | 0.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2023 | 16593 | 0.510 |
Why?
|
| Tumor Burden | 4 | 2016 | 2034 | 0.460 |
Why?
|
| Abiraterone Acetate | 5 | 2021 | 90 | 0.450 |
Why?
|
| Osteoclasts | 2 | 2009 | 158 | 0.400 |
Why?
|
| Dasatinib | 8 | 2020 | 881 | 0.380 |
Why?
|
| Receptors, Androgen | 4 | 2021 | 922 | 0.360 |
Why?
|
| Radium | 3 | 2016 | 97 | 0.350 |
Why?
|
| Prostate-Specific Antigen | 5 | 2021 | 1037 | 0.350 |
Why?
|
| Androgen Antagonists | 3 | 2021 | 434 | 0.340 |
Why?
|
| Food | 1 | 2009 | 156 | 0.320 |
Why?
|
| Positron-Emission Tomography | 3 | 2016 | 2198 | 0.320 |
Why?
|
| Radiotherapy | 1 | 2016 | 1858 | 0.320 |
Why?
|
| Bone Marrow | 1 | 2016 | 2434 | 0.310 |
Why?
|
| Circadian Rhythm | 1 | 2009 | 327 | 0.290 |
Why?
|
| Herpesvirus 6, Human | 2 | 1997 | 81 | 0.260 |
Why?
|
| Kidney Neoplasms | 5 | 2021 | 3142 | 0.250 |
Why?
|
| Radioisotopes | 2 | 2016 | 176 | 0.240 |
Why?
|
| Ipilimumab | 2 | 2021 | 758 | 0.230 |
Why?
|
| Feeding Behavior | 1 | 2009 | 826 | 0.220 |
Why?
|
| Biomarkers, Tumor | 7 | 2024 | 10698 | 0.210 |
Why?
|
| Male | 39 | 2024 | 128346 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2021 | 2412 | 0.200 |
Why?
|
| Ketone Bodies | 1 | 2021 | 57 | 0.200 |
Why?
|
| Kallikreins | 1 | 2021 | 87 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2014 | 4956 | 0.180 |
Why?
|
| Antineoplastic Agents | 8 | 2020 | 14678 | 0.180 |
Why?
|
| Precision Medicine | 3 | 2020 | 1201 | 0.180 |
Why?
|
| Aged, 80 and over | 13 | 2021 | 30941 | 0.180 |
Why?
|
| Radiopharmaceuticals | 2 | 2016 | 1338 | 0.170 |
Why?
|
| Prednisone | 5 | 2021 | 1039 | 0.170 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2016 | 1259 | 0.170 |
Why?
|
| Drug Administration Schedule | 3 | 2021 | 3538 | 0.170 |
Why?
|
| Urothelium | 1 | 2020 | 272 | 0.160 |
Why?
|
| Aged | 21 | 2021 | 73156 | 0.160 |
Why?
|
| Phenylthiohydantoin | 1 | 2019 | 106 | 0.160 |
Why?
|
| Prostatectomy | 2 | 2021 | 1005 | 0.150 |
Why?
|
| Mice | 17 | 2024 | 35988 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 3349 | 0.150 |
Why?
|
| Humans | 44 | 2024 | 270757 | 0.150 |
Why?
|
| Bovine papillomavirus 1 | 1 | 1997 | 12 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2024 | 3920 | 0.150 |
Why?
|
| Middle Aged | 21 | 2021 | 90004 | 0.150 |
Why?
|
| Tissue Extracts | 1 | 2017 | 50 | 0.150 |
Why?
|
| Insulin | 2 | 2016 | 1510 | 0.150 |
Why?
|
| Viral Proteins | 2 | 1997 | 494 | 0.140 |
Why?
|
| Bridged-Ring Compounds | 1 | 2017 | 180 | 0.140 |
Why?
|
| Ureteral Neoplasms | 1 | 2019 | 236 | 0.140 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2016 | 39 | 0.140 |
Why?
|
| Cell Transformation, Viral | 1 | 1997 | 174 | 0.140 |
Why?
|
| Animals | 19 | 2024 | 62754 | 0.140 |
Why?
|
| Naphthalenes | 1 | 2016 | 84 | 0.130 |
Why?
|
| Brain | 1 | 2009 | 4248 | 0.130 |
Why?
|
| Osteopontin | 1 | 2016 | 146 | 0.130 |
Why?
|
| Neoplasm Metastasis | 6 | 2021 | 5324 | 0.130 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2016 | 154 | 0.130 |
Why?
|
| Genes, ras | 2 | 1997 | 680 | 0.130 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 485 | 0.120 |
Why?
|
| Multimodal Imaging | 2 | 2016 | 551 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2012 | 7936 | 0.120 |
Why?
|
| Strontium Radioisotopes | 1 | 2014 | 31 | 0.120 |
Why?
|
| Fluorine Radioisotopes | 1 | 2015 | 139 | 0.120 |
Why?
|
| Clonal Evolution | 1 | 2016 | 251 | 0.120 |
Why?
|
| Recombinational DNA Repair | 1 | 2014 | 78 | 0.110 |
Why?
|
| 3T3 Cells | 5 | 2013 | 387 | 0.110 |
Why?
|
| Disease Progression | 3 | 2021 | 6891 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2020 | 4507 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1997 | 1119 | 0.110 |
Why?
|
| Signal Transduction | 5 | 2021 | 12204 | 0.100 |
Why?
|
| Choroid Neoplasms | 1 | 2012 | 46 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2014 | 2471 | 0.100 |
Why?
|
| Leuprolide | 1 | 2012 | 67 | 0.100 |
Why?
|
| Triazoles | 1 | 2016 | 630 | 0.100 |
Why?
|
| Treatment Outcome | 12 | 2023 | 33785 | 0.100 |
Why?
|
| BRCA2 Protein | 1 | 2014 | 370 | 0.100 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2019 | 1011 | 0.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 630 | 0.100 |
Why?
|
| Castration | 1 | 2011 | 128 | 0.100 |
Why?
|
| Osteoblasts | 2 | 2013 | 394 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 1335 | 0.090 |
Why?
|
| HIV-1 | 1 | 1995 | 641 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2014 | 853 | 0.090 |
Why?
|
| Cell Line, Tumor | 6 | 2021 | 14864 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2010 | 96 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3393 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2024 | 9078 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2013 | 1432 | 0.090 |
Why?
|
| Bone and Bones | 2 | 2015 | 612 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1997 | 1408 | 0.090 |
Why?
|
| Suprachiasmatic Nucleus | 1 | 2009 | 13 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2010 | 83 | 0.090 |
Why?
|
| Photoperiod | 1 | 2009 | 24 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 649 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 10349 | 0.090 |
Why?
|
| Neoplasms | 3 | 2011 | 15849 | 0.080 |
Why?
|
| Glucagon | 1 | 2009 | 202 | 0.080 |
Why?
|
| Vagus Nerve | 1 | 2009 | 70 | 0.080 |
Why?
|
| Ghrelin | 1 | 2009 | 78 | 0.080 |
Why?
|
| RANK Ligand | 1 | 2009 | 116 | 0.080 |
Why?
|
| Carcinoma | 1 | 2020 | 2627 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 1654 | 0.080 |
Why?
|
| Pyrroles | 1 | 2012 | 592 | 0.080 |
Why?
|
| Models, Neurological | 1 | 2009 | 241 | 0.080 |
Why?
|
| Disease-Free Survival | 5 | 2021 | 10249 | 0.080 |
Why?
|
| RNA, Long Noncoding | 1 | 2014 | 618 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 1995 | 3245 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 1 | 2010 | 427 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 1322 | 0.070 |
Why?
|
| Double-Blind Method | 1 | 2013 | 2616 | 0.070 |
Why?
|
| Leptin | 1 | 2009 | 313 | 0.070 |
Why?
|
| Neural Pathways | 1 | 2009 | 316 | 0.070 |
Why?
|
| Adult | 11 | 2021 | 81523 | 0.070 |
Why?
|
| Gene Expression Regulation, Viral | 3 | 1997 | 196 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 1995 | 3415 | 0.070 |
Why?
|
| Indoles | 1 | 2012 | 1035 | 0.070 |
Why?
|
| Collagen | 1 | 2009 | 737 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 6248 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 2 | 2014 | 1599 | 0.070 |
Why?
|
| Neoplasm Transplantation | 2 | 2021 | 1567 | 0.070 |
Why?
|
| Genes, Viral | 2 | 1997 | 257 | 0.070 |
Why?
|
| Monocytes | 1 | 2009 | 787 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2009 | 7294 | 0.060 |
Why?
|
| Mice, SCID | 3 | 2016 | 1855 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2009 | 985 | 0.060 |
Why?
|
| Prognosis | 6 | 2023 | 22452 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2018 | 486 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2009 | 1287 | 0.060 |
Why?
|
| Nephrectomy | 1 | 2009 | 806 | 0.060 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2010 | 741 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 5085 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2017 | 3532 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2021 | 39670 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 15237 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 7782 | 0.050 |
Why?
|
| Transcriptional Activation | 2 | 1997 | 1147 | 0.050 |
Why?
|
| Cell Survival | 1 | 2009 | 3081 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2011 | 2335 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2021 | 9304 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 1268 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2016 | 686 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2010 | 4190 | 0.050 |
Why?
|
| Heterografts | 1 | 2024 | 745 | 0.050 |
Why?
|
| Androstenes | 1 | 2020 | 44 | 0.040 |
Why?
|
| Rats | 1 | 2009 | 6635 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2021 | 182 | 0.040 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 1820 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2020 | 97 | 0.040 |
Why?
|
| Models, Biological | 1 | 2009 | 3225 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 203 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 3859 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 2669 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 421 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2018 | 228 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2021 | 562 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2021 | 448 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 747 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 7215 | 0.040 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2020 | 691 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2020 | 909 | 0.040 |
Why?
|
| Genes, Regulator | 1 | 1997 | 83 | 0.040 |
Why?
|
| Viral Structural Proteins | 1 | 1997 | 61 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 5161 | 0.040 |
Why?
|
| Base Sequence | 2 | 2011 | 5494 | 0.040 |
Why?
|
| Dehydroepiandrosterone | 1 | 2016 | 34 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 667 | 0.030 |
Why?
|
| ROC Curve | 1 | 2020 | 1221 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 13976 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2011 | 6784 | 0.030 |
Why?
|
| Skeleton | 1 | 2015 | 8 | 0.030 |
Why?
|
| HIV Long Terminal Repeat | 1 | 1995 | 28 | 0.030 |
Why?
|
| Mice, Nude | 3 | 2013 | 4360 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2016 | 406 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 6169 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 1996 | 371 | 0.030 |
Why?
|
| Whole Body Imaging | 1 | 2015 | 113 | 0.030 |
Why?
|
| Female | 8 | 2021 | 148398 | 0.030 |
Why?
|
| Time Factors | 3 | 2021 | 13102 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 1997 | 3657 | 0.030 |
Why?
|
| Nitriles | 1 | 2019 | 943 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 730 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 532 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1088 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 340 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 1996 | 493 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1995 | 1091 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2013 | 100 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 1997 | 642 | 0.030 |
Why?
|
| Oncogenes | 1 | 1997 | 700 | 0.030 |
Why?
|
| Benzamides | 1 | 2019 | 1883 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 595 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 1542 | 0.030 |
Why?
|
| Glutamates | 1 | 2013 | 134 | 0.030 |
Why?
|
| Androgens | 1 | 2016 | 558 | 0.030 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2014 | 163 | 0.030 |
Why?
|
| Cisplatin | 1 | 2020 | 2493 | 0.030 |
Why?
|
| Guanine | 1 | 2013 | 157 | 0.030 |
Why?
|
| DNA Primers | 1 | 1995 | 1508 | 0.030 |
Why?
|
| Platinum | 1 | 2013 | 142 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 337 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2013 | 229 | 0.030 |
Why?
|
| Diphosphonates | 1 | 2014 | 264 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2014 | 324 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2012 | 249 | 0.030 |
Why?
|
| Phthalazines | 1 | 2014 | 262 | 0.020 |
Why?
|
| Survival Rate | 2 | 2016 | 12516 | 0.020 |
Why?
|
| Hospitalization | 1 | 2021 | 2195 | 0.020 |
Why?
|
| Cell Death | 1 | 2014 | 689 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2013 | 354 | 0.020 |
Why?
|
| Down-Regulation | 1 | 1996 | 2109 | 0.020 |
Why?
|
| Peptides | 1 | 1997 | 1529 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 1437 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2020 | 13343 | 0.020 |
Why?
|
| Trans-Activators | 1 | 1997 | 1655 | 0.020 |
Why?
|
| Osteonectin | 1 | 2010 | 56 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 2288 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2013 | 621 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 1538 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 339 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 1398 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2014 | 513 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 2984 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 4641 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 3544 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2013 | 528 | 0.020 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2008 | 27 | 0.020 |
Why?
|
| Imidazoles | 1 | 2014 | 1059 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2013 | 1377 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2009 | 397 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2012 | 873 | 0.020 |
Why?
|
| Research Design | 1 | 2015 | 1568 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2008 | 116 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 3536 | 0.020 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 4787 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2014 | 3138 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 1084 | 0.020 |
Why?
|
| Tyrosine | 1 | 2008 | 510 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4385 | 0.020 |
Why?
|
| DNA Damage | 1 | 2014 | 1980 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 1934 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2009 | 959 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 2848 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 5104 | 0.020 |
Why?
|
| Piperazines | 1 | 2014 | 2153 | 0.020 |
Why?
|
| Wound Healing | 1 | 2009 | 750 | 0.010 |
Why?
|
| Quinazolines | 1 | 2009 | 953 | 0.010 |
Why?
|
| Young Adult | 2 | 2013 | 22044 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 662 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2009 | 2345 | 0.010 |
Why?
|
| Risk Factors | 1 | 2020 | 17819 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 9040 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 11761 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 4371 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 4985 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 4067 | 0.010 |
Why?
|
| Transfection | 2 | 1997 | 3169 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 3972 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 5834 | 0.010 |
Why?
|
| Cell Movement | 1 | 2008 | 2500 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 4967 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 6829 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1997 | 141 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 1996 | 319 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1996 | 431 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 5188 | 0.010 |
Why?
|
| Rabbits | 1 | 1996 | 1089 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 7460 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 32515 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1997 | 1884 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1996 | 1742 | 0.010 |
Why?
|